61381-04-2

Basic information

• Product Name: 3,4-Diethoxyphenethylamine
• Synonyms: TIMTEC-BB SBB001870;RARECHEM AL BW 0522;3,4-DIETHOXYBENZENE ETHANAMINE;3,4-DIETHOXYPHENETHYLAMINE;3,4-DIETHOXYPHENYLETHYLAMINE;3,4-DIETHYLOXY PHENYL ETHYLAMINE;2-(3,4-DIETHOXYPHENYL)ETHANAMINE;2-(3,4-DIETHOXY-PHENYL)-ETHYLAMINE
• CAS NO: 61381-04-2
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28
• EINECS: 262-752-8
• Mol File: 61381-04-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 311.4 °C at 760 mmHg
• Flash Point: 155.2 °C
• Appearance: Colorless to yellow clear liquid
• Density: 1.011 g/cm³
• Vapor Pressure: 0.000563mmHg at 25°C
• PKA: 9.75±0.10(Predicted)
• CAS DataBase Reference: 3,4-Diethoxyphenethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Diethoxyphenethylamine(61381-04-2)
• EPA Substance Registry System: 3,4-Diethoxyphenethylamine(61381-04-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 61381-04-2(Hazardous Substances Data)

Usage

General Description

3,4-Diethoxyphenethylamine is a chemical compound with the molecular formula C12H19NO2. It is a derivative of phenethylamine and has two ethoxy (C2H5O) groups attached to the phenyl ring at the 3 and 4 positions. The compound is a psychoactive drug with potential effects on the central nervous system, although its specific pharmacological properties and potential uses have not been extensively studied. Like other phenethylamine derivatives, it may have stimulant, entactogenic, and psychedelic effects when consumed, and it is considered a controlled substance in many countries due to its psychoactive properties. Its potential for abuse and lack of scientific research on its safety and efficacy make it a subject of regulatory scrutiny and limited medical use.

InChI:InChI=1/C12H19NO2/c1-3-14-11-6-5-10(7-8-13)9-12(11)15-4-2/h5-6,9H,3-4,7-8,13H2,1-2H3/p+1

Upstream product

• 38464-04-9 3,4-diethoxy-phenyl-acetic acid 
• 53017-34-8 ethyl 2-(3,4-diethoxyphenyl)-2-oxoacetate 
• 2050-46-6 1,2-diethoxybenzene 
• 1137-71-9 1-(3,4-diethoxyphenyl)ethanone 
• 526190-09-0 2-(3,4-diethoxyphenyl)acetamide 
• 92157-09-0 methyl 2-(3,4-diethoxyphenyl)acetate 
• 69373-87-1 ethyl 2-(3,4-diethoxyphenyl)acetate 
• 1005009-95-9 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 279262-08-7 3,4-diethoxyphenylboronic acid 
• 53207-08-2 4-bromo-1,2-diethoxybenzene 
• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 37034-31-4 N-(tert-butoxycarbonyl)dopamine 
• 1075748-15-0 tert-butyl N-[2-(3,4-diethoxyphenyl)ethyl]carbamate 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 102708-64-5 N-(3,4-diethoxy-phenethyl)-heptanamide 
• 102012-61-3 (6,7-diethoxy-3,4-dihydro-isoquinolin-1-yl)-phenyl-methanone 
• 690697-07-5 3,4,5-trimethoxy-benzoic acid-(3,4-diethoxy-phenethylamide) 
• 102597-59-1 N-(3,4-diethoxy-phenethyl)-transcinnamamide 
• 1037942-87-2 3,4,5-triethoxy-benzoic acid-(3,4-diethoxy-phenethylamide) 
• 102178-92-7 3,5-dinitro-benzoic acid-(3,4-diethoxy-phenethylamide) 

Relevant articles and documents

Novel method for preparing drotaverine hydrochloride intermediate

The invention discloses a novel method for preparing a drotaverine hydrochloride intermediate, belonging to the technical field of medicine synthesis. The preparation method comprises the following steps: preparing an intermediate 3,4-diethoxyphenylacetic acid with 1,2-diethoxybenzene as a raw material, and preparing the intermediate 3,4-diethoxyphenylacetamide with 3,4-diethoxyphenylacetic acid as a raw material. According to the novel process for preparing the drotaverine hydrochloride intermediate, a method for directly preparing 3,4-diethoxyphenylacetic acid and 3,4-diethoxyphenylethylamine is adopted, and a process for preparing 3,4-diethoxyphenylacetonitrile is avoided, so a reaction step of using sodium cyanide is avoided.

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

BRIDGED SIX-MEMBERED RING COMPOUNDS

The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.